These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 12088172

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH.
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [Abstract] [Full Text] [Related]

  • 3. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V, Cardiac Safety in Schizophrenia Group.
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C, Canceil O, Iaria P.
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM.
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
    Lawrence KR, Nasraway SA.
    Pharmacotherapy; 1997 Jun; 17(3):531-7. PubMed ID: 9165555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW, Kirk MA, Evers SJ, Rosenfeld SH.
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [Abstract] [Full Text] [Related]

  • 13. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P, Hreiche R, Turgeon J.
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [Abstract] [Full Text] [Related]

  • 14. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL, Lau YS, Teo WS.
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [Abstract] [Full Text] [Related]

  • 15. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
    Perrin-Terrin A, Pathak A, Lapeyre-Mestre M.
    Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V, Cavero I.
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [Abstract] [Full Text] [Related]

  • 20. Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.
    Bar-Meir E, Schein O, Eisenkraft A, Rubinshtein R, Grubstein A, Militianu A, Glikson M, CBRN Medical Branch, Medical Corps, Israel Defense Forces.
    Crit Rev Toxicol; 2007 Mar; 37(3):279-85. PubMed ID: 17453935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.